Publications from the RAS Initiative

The NCI RAS Initiative has a "hub-and-spokes" structure, in that its scientists work both independently and in collaboration with academic and commercial entities. The list of RAS Initiative publications below reflects the balance between the public responsibilities of the National Cancer Institute and the requirements of our external partners.

Authors who names are marked with an asterisk (*) are part of the RAS Initiative.

  • The bacterial Ras/Rap1 site-specific endopeptidase RRSP cleaves Ras through an atypical mechanism to disrupt Ras-ERK signaling
    Biancucci M, Minasov G, Banerjee A, Herrera A, Woida PJ, Kieffer MB, Bindu L*, Abreu-Blanco M*, Anderson WF, Gaponenko V, Stephen AG*, Holderfield M*, Satchell KJF
    Sci Signal 2018
    PubMed ID: 30279169
  • Production of authentic geranylgeranylated KRAS4b using an engineered baculovirus system
    Procter L*, Grose C*, Esposito D*
    Protein Expr Purif 2018 
    PubMed ID: 29936133
  • Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics
    Ye X*, Luke BT, Wei BR, Kaczmarczyk JA, Loncarek J, Dwyer JE, Johann DJ, Saul RG, Nissley DV*, McCormick F*, Whiteley GR*, Blonder J*
    Oncotarget 2018 
    PubMed ID: 29899869
  • Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain
    Travers T, López CA, Van QN*, Neale C, Tonelli M, Stephen AG*, Gnanakaran S
    Sci Rep 2018
    PubMed ID: 29855542
  • Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk
    Ntai I, Fornelli L, DeHart CJ, Hutton JE, Doubleday PF, LeDuc RD, van Nispen AJ, Fellers RT, Whiteley G*, Boja ES, Rodriguez H, Kelleher NL
    Proc Natl Acad Sci USA 2018
    PubMed ID: 29610327
  • Differential Effector Engagement by Oncogenic KRAS
    Yuan TL, Amzallag A, Bagni R*, Yi M*, Afghani S, Burgan W*, Fer N*, Strathern LA*, Powell K*, Smith B, Waters AM*, Drubin D, Thomson T, Liao R, Greninger P, Stein GT, Murchie E, Cortez E, Egan RK, Procter L*, Bess M, Cheng KT*, Lee CS, Lee LC, Fellmann C, Stephens R*, Luo J, Lowe SW, Benes CH, McCormick F*
    Cell Rep 2018
    PubMed ID: 29444439
  • New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics
    Esposito D*, Stephen AG*, Turbyville TJ*, Holderfield M*
    Semin Cancer Biol. 2018 
    PubMed ID: 29432816
  • Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins
    Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G*, Blonder J*, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA
    Elife 2018 
    PubMed ID: 29359686
  • K-Ras4B Remains Monomeric on Membranes over a Wide Range of Surface Densities and Lipid Compositions
    Chung JK, Lee YK, Denson JP*, Gillette WK*, Alvarez S, Stephen AG*, Groves JT
    Biophys J. 2018 
    PubMed ID: 29320680
  • Efforts to Develop KRAS Inhibitors
    Holderfield M*
    Cold Spring Harb Perspect Med 2018
    PubMed ID: 29101115
  • Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
    Waters AM*, Ozkan-Dagliyan I, Vaseva AV, Fer N*, Strathern LA*, Hobbs GA, Tessier-Cloutier B, Gillette WK*, Bagni R*, Whiteley GR*, Hartley JL*, McCormick F*, Cox AD, Houghton PJ, Huntsman DG, Philips MR, Der CJ
    Sci Signal 2018
    PubMed ID: 28951536
  • RAS Proteins and Their Regulators in Human Disease
    Simanshu DK*, Nissley DV*, McCormick F*
    Cell 2017
    PubMed ID: 28666118
  • Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes
    Stephens RM*, Yi M*, Kessing B*, Nissley DV*, McCormick F*
    Cancer Inform 2017
    PubMed ID: 28634423
  • A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation
    Yin G, Kistler S, George SD, Kuhlmann N, Garvey L*, Huynh M, Bagni RK*, Lammers M, Der CJ, Campbell SL
    J Biol Chem 2017
    PubMed ID: 28154176
  • RAS signaling: Divide and conquer
    Holderfield M*, Morrison DK
    Nat Chem Biol 2016
    PubMed ID: 27984577
  • Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface
    Ye X, Chan KC, Waters AM*, Bess M, Harned A, Wei BR, Loncarek J, Luke BT, Orsburn BC, Hollinger BD*, Stephens RM*, Bagni R*, Martinko A, Wells JA, Nissley DV*, McCormick F*, Whiteley G*, Blonder J*
    Oncotarget 2016
    PubMed ID: 27894102
  • Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit
    Ritt DA, Abreu-Blanco MT*, Bindu L*, Durrant DE, Zhou M, Specht SI, Stephen AG*, Holderfield M*, Morrison DK
    Mol Cell 2016
    PubMed ID: 27889448
  • Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ
    Dharmaiah S*, Bindu L*, Tran TH*, Gillette WK*, Frank PH*, Ghirlando R, Nissley DV*, Esposito D*, McCormick F*, Stephen AG*, Simanshu DK*
    Proc Natl Acad Sci USA 2016
    PubMed ID: 27791178
  • Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells
    Waters AM*, Bagni R*, Portugal F*, Hartley JL*
    PLoS One 2016
    PubMed ID: 27684555
  • Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions
    Gillette WK*, Esposito D*, Abreu Blanco M*, Alexander P*, Bindu L*, Bittner C*, Chertov O*, Frank PH*, Grose C*, Jones JE*, Meng Z*, Perkins S*, Van Q, Ghirlando R, Fivash M*, Nissley DV*, McCormick F*, Holderfield M*, Stephen AG*
    Sci Rep 2015
    PubMed ID: 26522388
  • Progress in targeting RAF kinases for cancer therapy
    Turbyville TJ*, Holderfield M*
    Per Med 2015
    PubMed ID: 29771643
  • Dragging RAS back in the ring
    Stephen AG*, Esposito D*, Bagni RK*, McCormick F*
    Cancer Cell 2014
    PubMed ID: 24651010
  • Posted: October 16, 2018

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Publications from the RAS Initiative was originally published by the National Cancer Institute.”

We welcome your comments on this post. All comments must follow our comment policy.